233 related articles for article (PubMed ID: 35817829)
1. Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1.
Mabe NW; Huang M; Dalton GN; Alexe G; Schaefer DA; Geraghty AC; Robichaud AL; Conway AS; Khalid D; Mader MM; Belk JA; Ross KN; Sheffer M; Linde MH; Ly N; Yao W; Rotiroti MC; Smith BAH; Wernig M; Bertozzi CR; Monje M; Mitsiades CS; Majeti R; Satpathy AT; Stegmaier K; Majzner RG
Nat Cancer; 2022 Aug; 3(8):976-993. PubMed ID: 35817829
[TBL] [Abstract][Full Text] [Related]
2. The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of
Pilgrim AA; Jonus HC; Ho A; Cole AC; Shim J; Goldsmith KC
Oncoimmunology; 2023; 12(1):2240678. PubMed ID: 37554309
[TBL] [Abstract][Full Text] [Related]
3. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy.
Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H
Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879
[TBL] [Abstract][Full Text] [Related]
4. Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance.
Tibbetts R; Yeo KK; Muthugounder S; Lee MH; Jung C; Porras-Corredor T; Sheard MA; Asgharzadeh S
Cancer Immunol Immunother; 2022 Jan; 71(1):153-164. PubMed ID: 34043024
[TBL] [Abstract][Full Text] [Related]
5. Combined sialic acid and histone deacetylase (HDAC) inhibitor treatment up-regulates the neuroblastoma antigen GD2.
van den Bijgaart RJE; Kroesen M; Wassink M; Brok IC; Kers-Rebel ED; Boon L; Heise T; van Scherpenzeel M; Lefeber DJ; Boltje TJ; den Brok MH; Hoogerbrugge PM; Büll C; Adema GJ
J Biol Chem; 2019 Mar; 294(12):4437-4449. PubMed ID: 30670592
[TBL] [Abstract][Full Text] [Related]
6. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
7.
McNerney KO; Karageorgos S; Ferry GM; Wolpaw AJ; Burudpakdee C; Khurana P; Toland CN; Vemu R; Vu A; Hogarty MD; Bassiri H
Oncoimmunology; 2022; 11(1):2075204. PubMed ID: 35646475
[TBL] [Abstract][Full Text] [Related]
8. Anti-GD2 immunotherapy for neuroblastoma.
Sait S; Modak S
Expert Rev Anticancer Ther; 2017 Oct; 17(10):889-904. PubMed ID: 28780888
[TBL] [Abstract][Full Text] [Related]
9. Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells.
Di Matteo S; Bilotta MT; Pelosi A; Haas D; Theinert T; Weber G; Schlegel PG; Berg M; Moretta L; Maggi E; Azzarone B; Vacca P; Tumino N; Caruana I
Front Immunol; 2024; 15():1382931. PubMed ID: 38736882
[TBL] [Abstract][Full Text] [Related]
10. Anti-GD2 antibody and Vorinostat immunocombination therapy is highly effective in an aggressive orthotopic neuroblastoma model.
van den Bijgaart RJE; Kroesen M; Brok IC; Reijnen D; Wassink M; Boon L; Hoogerbrugge PM; Adema GJ
Oncoimmunology; 2020 Sep; 9(1):1817653. PubMed ID: 33457098
[TBL] [Abstract][Full Text] [Related]
11. Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma.
Chan GC; Chan CM
Biomolecules; 2022 Feb; 12(3):. PubMed ID: 35327550
[TBL] [Abstract][Full Text] [Related]
12. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins.
Cheresh DA; Pierschbacher MD; Herzig MA; Mujoo K
J Cell Biol; 1986 Mar; 102(3):688-96. PubMed ID: 3005335
[TBL] [Abstract][Full Text] [Related]
13. Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma.
Voeller J; Sondel PM
J Pediatr Hematol Oncol; 2019 Apr; 41(3):163-169. PubMed ID: 30897608
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
15. Relationship of glycosyltransferases and mRNA levels to ganglioside expression in neuroblastoma and melanoma cells.
Ruan S; Raj BK; Lloyd KO
J Neurochem; 1999 Feb; 72(2):514-21. PubMed ID: 9930722
[TBL] [Abstract][Full Text] [Related]
16. Ganglioside GD2 in reception and transduction of cell death signal in tumor cells.
Doronin II; Vishnyakova PA; Kholodenko IV; Ponomarev ED; Ryazantsev DY; Molotkovskaya IM; Kholodenko RV
BMC Cancer; 2014 Apr; 14():295. PubMed ID: 24773917
[TBL] [Abstract][Full Text] [Related]
17. Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
Seitz CM; Flaadt T; Mezger M; Lang AM; Michaelis S; Katz M; Syring D; Joechner A; Rabsteyn A; Siebert N; Troschke-Meurer S; Zumpe M; Lode HN; Yang SF; Atar D; Mast AS; Scheuermann S; Heubach F; Handgretinger R; Lang P; Schlegel P
Front Immunol; 2021; 12():690467. PubMed ID: 34367149
[TBL] [Abstract][Full Text] [Related]
18. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.
Zirngibl F; Ivasko SM; Grunewald L; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Astrahantseff K; Andersch L; Schulte JH; Lode HN; Eggert A; Anders K; Hundsdoerfer P; Künkele A
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34285106
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro.
Kawashima I; Tada N; Fujimori T; Tai T
J Biochem; 1990 Jul; 108(1):109-15. PubMed ID: 2121721
[TBL] [Abstract][Full Text] [Related]
20. Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma.
Roth M; Linkowski M; Tarim J; Piperdi S; Sowers R; Geller D; Gill J; Gorlick R
Cancer; 2014 Feb; 120(4):548-54. PubMed ID: 24166473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
